Elucidation of involvement and clinical application of angiopoietin in retinal vein occlusion with macular edema

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K18884
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 56060:Ophthalmology-related
• Research Institution: Nagoya City University
• Principal Investigator: Suzuki Norihiro 名古屋市立大学, 医薬学総合研究院(医学), 研究員 (10831258)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: 網膜静脈閉塞症 / 黄斑浮腫 / アンジオポエチン

Outline of Final Research Achievements

Intravitreal injection of anti-vascular endothelial growth factor (VEGF) has been benefical in improving the visual outcomes in patients with a retinal vein occlusion (RVO) with macular edema. However, there are still refractory cases or most patients need multiple injections of anti-VEGF agents. We focused on angiopoietin: Ang) as anew target in the treatment of RVO with macular edema. Ang is involved in RVO, suggesting that its control may be necessary.

Free Research Field

網膜静脈閉塞症

Academic Significance and Societal Importance of the Research Achievements

網膜静脈閉塞症 (retinal vein occlusion: RVO) の視力低下の主因は黄斑浮腫である。その黄斑浮腫に対する血管内皮増殖因子 (vascular endothelial growth factor: VEGF) 阻害療法は一定の効果をあげているが、治療抵抗例・再発例、頻回の治療が必要であるなど、課題が多い。今回我々は、マウスで実験的RVOモデルを作成し、RVOの病態解明を行った。RVOにおいてアンジオポエチン(angiopoietin: Ang)が関与しており、その制御が必要である可能性が示唆された。